Patent · US Active

Protein heterodimer and use thereof

US11795203B2 · kind B2 · utility

1Cited by
9References
8Claims
0Family size

Inventor

Key dates

Filing dateJul 30, 2019
Grant dateOct 24, 2023
Priority date—
Expiry dateJul 30, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are a protein heterodimer and the use thereof. The protein heterodimer comprises a first polypeptide chain and a second polypeptide chain different from the first polypeptide chain, wherein the first polypeptide chain comprises IL(interleukin)12a and a first factor fused to IL12a, the second polypeptide chain comprises IL12b and a second factor fused to IL12b, and the first factor and the second factor are each independently selected from a group consisting of: IL2, GMCSF(granulocyte-macrophage colony-stimulating factor), IL7, IL15, IL21 and FLT3L(FMS-like tyrosine kinase 3 ligand). The protein heterodimer can be used for treating tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.